ED drugs slapped with new warning

Here's a trade-off that could have been dreamed up by a Puritan: Treat your ED, go deaf. The FDA is adding new warnings of sudden hearing loss to three of the popular ED drugs--you know their names. The agency doesn't have proof that the drugs caused sudden deafness but decided to add the warning after digging up 29 reports of the problem since 1996. The scary part, agency officials said, was that these patients lost their hearing--in one ear only--within two days of starting on the meds, sometimes within hours. In a third of the cases, the loss was temporary.

- read the FDA warning
- check out the report from the Associated Press

Related Articles:
Gene therapy approach may work against ED. Report
Safety concerns force delay for Phase III ED trial. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.